IKECHI NNAWUCHI: Open Payments
NPI 1598798662 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$98,496 in 260 payments from 12 companies in 2025. Trend: 2023 $84,091 · 2024 $63,718 · 2025 $98,496
Speaker / faculty: $78,628Consulting: $7,600Food & beverage: $6,516Travel & lodging: $5,752
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 52 | $45,745 |
| Neurocrine BioSciences, Inc. | 46 | $41,614 |
| ABBVIE INC. | 22 | $7,518 |
| E.R. Squibb & Sons, L.L.C. | 35 | $823 |
| Vanda Pharmaceuticals Inc. | 20 | $736 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 26 | $673 |
| Teva Pharmaceuticals USA, Inc. | 18 | $388 |
| Lundbeck LLC | 20 | $383 |
| Alkermes, Inc. | 15 | $296 |
| Janssen Scientific Affairs, LLC | 1 | $149 |
Products named: INGREZZA, ABILIFY MAINTENA, REXULTI, VRAYLAR, COBENFY, CAPLYTA, FANAPT, ABILIFY ASIMTUFII.
Industry payments across DC — which companies pay providers there.
